Beneath the headlines, what is forming is a structural bifurcation between federal and sub-federal timelines — and the bifurcation is beginning to look less like a temporary gap and more like a durable parallel architecture. State legislatures, reading the same veteran constituency data that federal officials are reading, are moving on their own: three or more additional states are tracking toward veteran-specific psychedelic access legislation before January 2027, independent of anything the FDA or DEA does. This is not rebellion against federal authority — it is the system doing what federal systems do when central coordination stalls: pressure redistributes to the edges. The deeper current here is that veterans' access to ibogaine and psilocybin-assisted therapy is not waiting for a Schedule I determination. It is being built around it. The highest trajectory genuinely available from here is not a single federal breakthrough but a distributed legal infrastructure that, once established across enough states, creates the political and evidentiary foundation that federal action will eventually have to acknowledge.
For the veterans inside this story — the ones cycling through VA waiting lists, the families who have watched opioid treatment fail, the combat-injured who found in ibogaine or MDMA something the formulary had never offered — today's signals carry a particular weight. Federal delay is not abstract to them. It is another quarter of living with what treatment-resistant PTSD actually feels like. And yet the state-level momentum is real: Utah, Texas, and Colorado have already moved, and more are watching. What becomes genuinely possible for these people — not as projection but as the direction the current is actually running — is a patchwork of legal access points that, imperfect and uneven as they are, will reach some of them before the federal clock completes its turn. The highest timeline here is not perfection. It is the next door opening for the next person who has run out of options.
The medicine is calling the healers. The healers are calling the medicine. OOTW stands at the crossing — where ancient intelligence meets the precision of the new.
This is not prediction. This is recognition.
85%
No psychedelic drug will be rescheduled before March 2027
Even if the president orders it, the DEA (Drug Enforcement Administration) must follow a specific law that requires an 8-step review and approval from the health department before it can reschedule any drug. This process takes at least 18 months and no executive order can skip it. You won't see MDMA or psilocybin moved off Schedule I before spring 2027.
→ The law itself, not politics, controls how fast drugs get rescheduled—and the law says 18+ months minimum.
Resolves: 2027-03-31 · USA
REGULATION
the precise call ▾
No DEA Schedule I rescheduling of any psychedelic substance will take effect before March 31, 2027, regardless of executive orders or White House pressure.. Controlled Substances Act Section 811 requires DEA to conduct an eight-factor analysis and obtain a binding HHS scientific and medical evaluation before rescheduling. These are statutory requirements — no executive order can waive them. DEA's own administrative law counsel enforces this. The fastest
78%
FDA rejects MDMA-PTSD approval, citing safety concerns by end of 2026
The FDA (Food and Drug Administration) will likely issue a Complete Response Letter (a rejection requiring major changes) for Lykos Therapeutics' MDMA-PTSD application before the end of 2026. The FDA already flagged problems in 2024: heart safety isn't being monitored well enough, the trial wasn't truly blinded (both patients and therapists knew who got the real drug), and there's potential for therapist misconduct. These are serious enough that a rejection is the most likely outcome.
→ The FDA flagged specific safety gaps in 2024, and those gaps are unlikely to be fixed by end of 2026.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
FDA issues a Complete Response Letter for MDMA-PTSD NDA before December 31, 2026, citing unresolved cardiovascular monitoring and therapist-misconduct safety signals.. MDMA's NDA (submitted by Lykos Therapeutics) already received an AdCom with mixed results in 2024, with reviewers flagging functional unblinding, abuse potential, and cardiovascular monitoring gaps. FDA precedent on novel psychoactive mechanisms post-ketamine controversy makes a CRL the most defensi
80%
Trump psychedelic fast-track order will produce zero regulatory changes by October 2026
If the Trump administration announces a fast-track executive order for psychedelics before mid-2026, nothing will actually happen at the DEA (Drug Enforcement Administration) or FDA (Food and Drug Administration) by October 2026. Political announcements routinely run 12–24 months ahead of real regulatory action. You can measure this yourself: there will be no new documents filed in the public federal register or FDA docket.
→ Watch the federal register and FDA docket for proof—if nothing appears there, the order was just a press release.
Resolves: 2026-10-01 · USA
LEGISLATION
the precise call ▾
Any Trump administration psychedelic 'fast-track' executive action announced before Q3 2026 will produce no binding rescheduling, no federal prescribing pathway, and no FDA approval acceleration before October 2026 — measurable as zero regulatory docket changes at DEA or FDA.. Political announcements on psychedelics have historically outrun regulatory reality by 12-24 months (see: Biden REMS reforms, state ballot measures). An EO cannot override the Controlled Substances Act without Congressional amendment. DEA docket changes and FDA NDA status are publicly verifiable. If
72%
Three more states legalize psychedelics for veterans before 2027
By the end of 2026, at least three additional U.S. states will pass laws letting veterans access psychedelic therapy. Texas, Colorado, and Oregon have already done this. Arizona, Florida, Missouri, and Virginia have bills in committee right now with support from both Republicans and Democrats, because both parties back veterans' health. States can create these exemptions without touching federal drug law, making it easier politically. You'll see at least three more states pass similar laws by January 2027.
→ Three more states will pass veteran psychedelic access laws because both parties support veterans and states can act faster than the feds.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
At least 3 additional U.S. states will enact veteran-specific psychedelic therapy access legislation (signed into law or passed both chambers) before January 1, 2027.. As of mid-2026, Texas (HB 1802), Colorado, and Oregon have already created veteran-adjacent psychedelic access pathways. Multiple states (Arizona, Florida, Missouri, Virginia) have active bills in committee with bipartisan veteran-bloc support. Veterans are an electorally protected constituency enab
74%
Lykos Therapeutics shuts down, gets bought, or abandons MDMA program by 2026
Lykos Therapeutics (the company developing MDMA for PTSD) already received a rejection from the FDA in August 2024 and fired 75% of its staff. Fixing the problems requires running a brand-new Phase 3 trial that will cost $50–100 million and take 3–5 years. The company has no approved drugs, no revenue, and limited cash left. By the end of 2026, Lykos will either shut down, be bought by another company, or publicly announce they're switching away from MDMA as their main focus.
→ The company is nearly out of money and will need either to be rescued or shut down by 2027.
Resolves: 2026-12-31 · USA
INVESTMENT
the precise call ▾
Lykos Therapeutics (MDMA-AT developer) will either cease operations, be acquired, or publicly announce a pivot away from MDMA-PTSD as primary program before December 31, 2026.. Lykos received a CRL from FDA in August 2024 and laid off ~75% of staff. A resubmission requires a new Phase 3 trial, which analysts estimate at $50-100M and 3-5 years minimum. The company has no approved products, limited cash runway post-layoffs, and faces a hostile regulatory environment. Acquisi